Lead Sponsor

Washington University School of Medicine

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Female patients 18 years of age or older
•Biopsy-proven breast cancer
•Tumor estrogen-receptor and progesterone-receptor status already determined or scheduled to be determined at time of surgery without intervening therapy.
•Primary lesion size ≥ 1.5 cm as determined by imaging studies (ultrasonography, mammography, CT or MRI) or physical examination
•Able to give informed consent
•Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and / or documented hysterectomy), post menopausal (cessation of menses for more than 1 year), non lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of FFNP) is negative.

•No previous history of hormone therapy; NOTE - subjects who were treated with hormone therapy for reasons other than breast cancer or breast cancer prevention may be allowed to participate after review of history by the primary investigator
•Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years
•Unable to tolerate 60-90 minutes of PET imaging per imaging session

Related studies

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT06347068 · Breast Cancer, Relapse, and more

NCT07655934 · Breast Cancer

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)